Medtronic has acquired Osteotech, a company producing biologic products for regenerative healing, in a transaction valued at approximately $123 million, according to a Medtronic news release.
The acquisition will complement Medtronic Biologics' bone and healing portfolio as well as expand the company's presence in new orthopedic fields, such as foot, ankle and sports medicine. Osteotech products include Grafton demineralizing bone matrix, MagniFuse Bone Grafts and Plexur Biocomposites.
Read the Medtronic release on this acquisition.
Read other coverage on Medtronic:
- Medtronic Conducts Defeat-HF Trials Examining the Use of SCS to Prevent Heart Failure
- Medtronic Eliminates Two Executive Positions as Part of Restructuring
- Medtronic Launches SOVEREIGN Spinal System
The acquisition will complement Medtronic Biologics' bone and healing portfolio as well as expand the company's presence in new orthopedic fields, such as foot, ankle and sports medicine. Osteotech products include Grafton demineralizing bone matrix, MagniFuse Bone Grafts and Plexur Biocomposites.
Read the Medtronic release on this acquisition.
Read other coverage on Medtronic:
- Medtronic Conducts Defeat-HF Trials Examining the Use of SCS to Prevent Heart Failure
- Medtronic Eliminates Two Executive Positions as Part of Restructuring
- Medtronic Launches SOVEREIGN Spinal System